Escalating Dose Study for Safety, Tolerability and Pharmacokinetics After Single and Multiple Dermal Administration of Two BAY1003803 Formulation Types With Two Concentrations Each in Healthy Male Volunteers, Applying a Double-blind, Vehicle-controlled Design and Including a Positive Control Group
Phase of Trial: Phase I
Latest Information Update: 04 Oct 2017
At a glance
- Drugs BAY 1003803 (Primary)
- Indications Psoriasis
- Focus Adverse reactions
- Sponsors Bayer
- 28 Sep 2017 Planned End Date changed from 1 Sep 2017 to 5 Oct 2017.
- 28 Sep 2017 Status changed from active, no longer recruiting to discontinued.
- 10 Aug 2017 Planned End Date changed from 15 Oct 2017 to 1 Sep 2017.